Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients.
Department of Neurosurgery, the First Hospital of China Medical University, Shenyang, China
Wen
W
Cheng
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
Chuanbao
C
Zhang
Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, China
Xiufang
X
Ren
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
Zheng
Z
Wang
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
Xing
X
Liu
Department of Neurosurgery, the First Hospital of China Medical University, Shenyang, China
Sheng
S
Han
Department of Neurosurgery, the First Hospital of China Medical University, Shenyang, China
Anhua
A
Wu
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D044466:Asian People / Q000235:genetics; D001932:Brain Neoplasms / Q000235:genetics / Q000628:therapy*; D002681:China; D005260:Female; D005909:Glioblastoma / Q000235:genetics / Q000628:therapy*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D019635:Neurosurgical Procedures; D049451:Nomograms; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D000077204:Temozolomide / Q000627:therapeutic use; D055815:Young Adult
D018906:Antineoplastic Agents, Alkylating; D007521:Isocitrate Dehydrogenase; D000077204:Temozolomide